Log in

Relevant bibliographies by topics / Insuline – Agonistes

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Insuline – Agonistes'

Author: Grafiati

Published: 4 June 2021

Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Insuline – Agonistes.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Insuline – Agonistes"

1

Ye, Ji-Ming, Miguel A. Iglesias, David G. Watson та ін. "PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly". American Journal of Physiology-Endocrinology and Metabolism 284, № 3 (2003): E531—E540. http://dx.doi.org/10.1152/ajpendo.00299.2002.

Full text

Abstract:

Peroxisome proliferator-activated receptor (PPAR)α and PPARγ agonists lower lipid accumulation in muscle and liver by different mechanisms. We investigated whether benefits could be achieved on insulin sensitivity and lipid metabolism by the dual PPARα/γ agonist ragaglitazar in high fat-fed rats. Ragaglitazar completely eliminated high-fat feeding-induced liver triglyceride accumulation and visceral adiposity, like the PPARα agonist Wy-14643 but without causing hepatomegaly. In contrast, the PPARγ agonist rosiglitazone only slightly lessened liver triglyceride without affecting visceral adipos

APA, Harvard, Vancouver, ISO, and other styles

2

Yajima, Ken, Hiroshi Hirose, Haruhisa Fujita та ін. "Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/dbmice". American Journal of Physiology-Endocrinology and Metabolism 284, № 5 (2003): E966—E971. http://dx.doi.org/10.1152/ajpendo.00149.2002.

Full text

Abstract:

Although peroxisome proliferator-activated receptor (PPAR)γ agonists ameliorate insulin resistance, they sometimes cause body weight gain, and the effect of PPAR agonists on insulin secretion is unclear. We evaluated the effects of combination therapy with a PPARγ agonist, pioglitazone, and a PPARα agonist, bezafibrate, and a dual agonist, KRP-297, for 4 wk in male C57BL/6J mice and db/db mice, and we investigated glucose-stimulated insulin secretion (GSIS) by in situ pancreatic perfusion. Body weight gain in db/db mice was less with KRP-297 treatment than with pioglitazone or pioglitazone + b

APA, Harvard, Vancouver, ISO, and other styles

3

Kim Jun, Jeany. "Focus on New Diabetes Treatment Options with Cardiovascular Benefits." Journal of Contemporary Pharmacy Practice 66, no. 3 (2019): 34–40. http://dx.doi.org/10.37901/jcphp18-00029.

Full text

Abstract:

The landscape of diabetes treatment options has changed due to new diabetes drug approvals, changes in the Food and Drug Administration indications based on cardiovascular (CV) outcomes studies, as well as the approval of follow-on biologic insulins. Two new drugs were approved for type 2 diabetes mellitus including ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and semaglutide, a glucagon-like peptide-1 (GLP1) receptor agonist joining a number of other drugs in these classes. In addition, follow-on biologic insulins, such as long-acting Basaglar (insulin glargine), and rap

APA, Harvard, Vancouver, ISO, and other styles

4

Cresser, Justin, Arend Bonen, Adrian Chabowski та ін. "Oral administration of a PPAR-δ agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers". American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 299, № 2 (2010): R470—R479. http://dx.doi.org/10.1152/ajpregu.00431.2009.

Full text

Abstract:

Agonists targeting the nuclear receptor peroxisome proliferator-activated receptors (PPAR)-δ may be potential therapeutic agents for insulin-resistant related conditions, as they may be able to stimulate fatty acid (FA) oxidation and attenuate the accumulation of harmful lipid species in skeletal muscle. Several reports have demonstrated that PPAR-δ agonists improve whole body insulin sensitivity. However, whether these agonists exert their direct effects on glucose and FA metabolism in skeletal muscle, and specifically with different fiber types, is unknown. This study was undertaken to deter

APA, Harvard, Vancouver, ISO, and other styles

5

Zhang, Xianyang, Tengjiao Cui, Jinlin He, et al. "Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice." Proceedings of the National Academy of Sciences 112, no. 44 (2015): 13651–56. http://dx.doi.org/10.1073/pnas.1518540112.

Full text

Abstract:

Agonists of growth hormone-releasing hormone (GHRH) have been previously reported to promote growth, function, and engraftment of islet cells following transplantation. Here we evaluated recently synthesized GHRH agonists on the proliferation and biological functions of rat pancreatic β-cell line (INS-1) and islets. In vitro treatment of INS-1 cells with GHRH agonists increased cell proliferation, the expression of cellular insulin, insulin-like growth factor-1 (IGF1), and GHRH receptor, and also stimulated insulin secretion in response to glucose challenge. Exposure of INS-1 cells to GHRH ago

APA, Harvard, Vancouver, ISO, and other styles

6

Cariou, Bertrand, Narimène Belhatem, Esteban Jodar, et al. "Impact de l’IMC sur la réduction de l’HbA 1c sous IDegLira chez des diabétiques de type 2 insuffisamment contrôlés sous sulfamides, agonistes des récepteurs au GLP-1 ou insuline Glargine U100 : analyses d’études de phase IIIb." Diabetes & Metabolism 43, no. 2 (2017): A114. http://dx.doi.org/10.1016/s1262-3636(17)30437-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chang, Feng, Linda A. Jaber, Helen D. Berlie, and Mary Beth O'Connell. "Evolution of Peroxisome Proliferator-Activated Receptor Agonists." Annals of Pharmacotherapy 41, no. 6 (2007): 973–83. http://dx.doi.org/10.1345/aph.1k013.

Full text

Abstract:

OBJECTIVE: To discuss the evolution of peroxisome proliferator-activated receptor (PPAR) agonists from single site to multiple subtype or partial agonists for the treatment of type 2 diabetes, dyslipidemia, obesity, and the metabolic syndrome. DATA SOURCES: Information was obtained from MEDLINE (1966-March 2007) using search terms peroxisome proliferator-activated receptor agonist, PPAR dual agonist, PPAR α/γ agonist, PPAR pan agonist, partial PPAR, and the specific compound names. Other sources included pharmaceutical companies, the Internet, and the American Diabetes Association 64th-66th Sc

APA, Harvard, Vancouver, ISO, and other styles

8

Porskjær Christensen, Lars, та Rime Bahij El-Houri. "Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds". Molecules 23, № 10 (2018): 2431. http://dx.doi.org/10.3390/molecules23102431.

Full text

Abstract:

Type 2 diabetes (T2D) is a metabolic disorder where insulin-sensitive tissues show reduced sensitivity towards insulin and a decreased glucose uptake (GU), which leads to hyperglycaemia. Peroxisome proliferator-activated receptor (PPAR)γ plays an important role in lipid and glucose homeostasis and is one of the targets in the discovery of drugs against T2D. Activation of PPARγ by agonists leads to a conformational change in the ligand-binding domain, a process that alters the transcription of several target genes involved in glucose and lipid metabolism. Depending on the ligands, they can indu

APA, Harvard, Vancouver, ISO, and other styles

9

Montessuit, Christophe, Irène Papageorgiou, and René Lerch. "Nuclear Receptor Agonists Improve Insulin Responsiveness in Cultured Cardiomyocytes through Enhanced Signaling and Preserved Cytoskeletal Architecture." Endocrinology 149, no. 3 (2007): 1064–74. http://dx.doi.org/10.1210/en.2007-0656.

Full text

Abstract:

Insulin resistance is the failure of insulin to stimulate the transport of glucose into its target cells. A highly regulatable supply of glucose is important for cardiomyocytes to cope with situations of metabolic stress. We recently observed that isolated adult rat cardiomyocytes become insulin resistant in vitro. Insulin resistance is combated at the whole body level with agonists of the nuclear receptor complex peroxisome proliferator-activated receptor γ (PPARγ)/retinoid X receptor (RXR). We investigated the effects of PPARγ/RXR agonists on the insulin-stimulated glucose transport and on i

APA, Harvard, Vancouver, ISO, and other styles

10

Balakumar, Pitchai, Nanjaian Mahadevan та Ramanathan Sambathkumar. "A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia". Current Molecular Pharmacology 12, № 3 (2019): 195–201. http://dx.doi.org/10.2174/1874467212666190111165015.

Full text

Abstract:

Background: Diabetes mellitus and concomitant dyslipidemia, being referred to as ‘diabetic dyslipidemia’, are the foremost detrimental factors documented to play a pivotal role in cardiovascular illness. Diabetic dyslipidemia is associated with insulin resistance, high plasma triglyceride levels, low HDL-cholesterol concentration and elevated small dense LDL-cholesterol particles. Maintaining an optimal glucose and lipid levels in patients afflicted with diabetic dyslipidemia could be a major task that might require a well-planned diet-management system and regular physical activity, or otherw

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Insuline – Agonistes"

1

Lavigne, Charles. "Effets de la nature des protéines alimentaires sur la prévention de la résistance à l'insuline chez le rat." Thesis, Université Laval, 2006. http://www.theses.ulaval.ca/2006/23771/23771.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dubois, Mathilde. "Dysfonctionnement des cellules β au cours du diabète de type 2 : rôle de la glucotoxicité et de la lipotoxicité et influence du Peroxisome Proliferator-Activated Receptor γ". Lille 2, 2003. http://www.theses.fr/2003LIL2P009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Silva, Silvana Auxiliadora Bordin da. "Mecanismos ionicos envolvidos na regulação da secreção de insulina por agonistas muscarinicos." [s.n.], 1995. http://repositorio.unicamp.br/jspui/handle/REPOSIP/313942.

Full text

Abstract:

Orientadores: Antonio Carlos Boschero, Antonio Ari Gonçalves<br>Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia<br>Made available in DSpace on 2018-07-21T02:38:56Z (GMT). No. of bitstreams: 1 Silva_SilvanaAuxiliadoraBordinda_D.pdf: 7203388 bytes, checksum: c77a4e34c567f2a9f3b4744751eab31c (MD5) Previous issue date: 1995<br>Resumo: O presente trabalho teve como proposta caracterizar o subtipo funcional de mAChR na célula ß pancreática, bem como elucidar os mecanismos iônicos envolvidos na estimulação muscarínica. Para isto, foram utilizadas ilhotas de ratos e camun

APA, Harvard, Vancouver, ISO, and other styles

4

Yimlamai, Tossaporn. "The effects of hindlimb unweighting and beta2-agonist on the ubiquitin-proteasome pathway and insulin-like growth factor i." [Gainesville, Fla.] : University of Florida, 2004. http://purl.fcla.edu/fcla/etd/UFE0003660.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Freitas, Fatima Rodrigues de Sousa e. "Efeito da reposição do hormônio do crescimento (GH) no desenvolvimento ósseo de ratas hipotireoideas tratadas com o agonista seletivo do receptor b de hormônio tireoideano GC-1." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/42/42131/tde-08092008-115022/.

Full text

Abstract:

Sabe-se que o hipotireoidismo (Hipo) resulta em supressão do eixo hormônio de crescimento (GH)/ insulin-like growth factor I (IGF-I) e em atraso no desenvolvimento esquelético. Em um estudo anterior, vimos que o tratamento de ratas jovens Hipo com GC-1, um análogo da triiodotironina (T3) seletivo pela isoforma <font face=\"symbol\">b de receptor de hormônio tireoideano (TR<font face=\"symbol\">b), não teve efeito sobre o IGF-I sérico ou sobre a expressão protéica de IGF-I nas lâminas epifisiais, mas parcialmente reverteu alterações esqueléticas decorrentes do Hipo, o que sugere que: (i) o dese

APA, Harvard, Vancouver, ISO, and other styles

6

Ferreira, Mari Cassol. "Análise da resposta hormonal pancreática antes e após tratamento com GLP-1 mimético em indivíduos com diabetes tipo 2 portadores da variante rs7903146 do gene TCF7L2." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/5/5135/tde-01112013-113904/.

Full text

Abstract:

Introdução: O gene TCF7L2 (Transcription Factor 7-Like 2) codifica o fator de transcrição de mesmo nome que, tem importante papel na via Wnt de sinalização intra celular. A via Wnt é constituída por proteínas de integração e ligação dos processos de diferenciação e multiplicação celulares, interagindo com os fatores TCF, e ativando a expressão de genes relacionados ao TCF7L2, sendo este amplamente expresso em vários tecidos. Dados epidemiológicos atuais não deixam dúvidas quanto à forte associação de polimorfismos do gene TCF7L2 com o diabetes tipo 2 (DM2) em diferentes etnias. Apesar de serem

APA, Harvard, Vancouver, ISO, and other styles

7

Abd, El Aziz Mirna Safia [Verfasser], Juris [Gutachter] Meier, and Horst Harald [Gutachter] Klein. "Metaanalyse von direkten Vergleichsstudien zwischen GLP-1 Rezeptor-Agonisten und Insulin in der Therapie des Typ 2 Diabetes : Unterschied zwischen kurz- und lang-wirksamen Präparaten? / Mirna Safia Abd El Aziz ; Gutachter: Juris Meier, Horst Harald Klein ; Medizinische Fakultät." Bochum : Ruhr-Universität Bochum, 2019. http://d-nb.info/1180028171/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fetter, Katie L. "Efficacy of Bydureon in Adults with Type 2 Diabetes." UNF Digital Commons, 2014. http://digitalcommons.unf.edu/etd/490.

Full text

Abstract:

Type 2 diabetes is still rapidly on the rise today, affecting 10.5% of individuals in the United States between the ages 45 to 64 and 18.4% of those between the ages of 65 to 74. In the past two decades, type 2 diabetes has doubled in all age groups. Many adults with type 2 diabetes experience difficulty managing their blood sugars, which can result in a range of further complications. One of the newest treatment options on the market today is a glucagon-like peptide-1 (GLP-1) receptor agonist, Bydureon. Similar to Byetta, Bydureon has a main ingredient of exenatide. It offers once a week dosi

APA, Harvard, Vancouver, ISO, and other styles

9

Barbosa, Joana Rafaela Sousa. "Simultaneous administration of insulin and GLP-1 agonists. Technologically possible?" Master's thesis, 2017. http://hdl.handle.net/10316/83770.

Full text

Abstract:

Relatório de Estágio do Mestrado Integrado em Ciências Farmacêuticas apresentado à Faculdade de Farmácia<br>A prática regular de exercício físico juntamente com uma alimentação equilibradasão, nos dias de hoje, fundamentais para a implementação de um estilo de vida saudável, sendo este indispensável quer para a prevenção como para o controlo de várias doenças.A diabetes mellitus, cuja prevalência tem aumentado drasticamente, também obedecea este conjunto de ditas medidas não farmacológicas, como primeiro passo de atuação. No entanto, esta abordagem na maior parte dos casos não é suficiente, se

APA, Harvard, Vancouver, ISO, and other styles

10

Cunha, Sara Sofia da Silva. "O Potencial Terapêutico dos Agonistas do GLP-1R na Doença de Alzheimer." Master's thesis, 2018. http://hdl.handle.net/10316/84718.

Full text

Abstract:

Relatório de Estágio do Mestrado Integrado em Ciências Farmacêuticas apresentado à Faculdade de Farmácia<br>A doença de Alzheimer é a doença neurodegenerativa mais comum e é caracterizadapela deterioração progressiva e irreversível das funções cognitivas. As principaiscaraterísticas histopatológicas da doença de Alzheimer compreendem a presença de placasamiloides extracelulares e de emaranhados neurofibrilares intracelulares. Apesar doconhecimento sobre a doença ser cada vez maior, ainda carece de uma terapêutica eficaz ecapaz de reverter ou, até mesmo, retardar a progressão da doença, constit

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Insuline – Agonistes"

1

Mendosa, David. Losing weight with your diabetes medication: How Byetta and other drugs can help you lose more weight than you ever thought possible. Da Capo Life Long, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mendosa, David. Losing weight with your diabetes medication: How Byetta and other drugs can help you lose more weight than you ever thought possible. Da Capo Life Long, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

(Foreword), Joe Prendergast, ed. Losing Weight with Your Diabetes Medication: How Byetta and Other Drugs Can Help You Lose More Weight than You Ever Thought Possible (Marlowe Diabetes Library). Marlowe & Company, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Cropsey, Christopher L., and Patrick B. Knight. Beta Blocker/Calcium Channel Blocker Overdose. Edited by Matthew D. McEvoy and Cory M. Furse. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190226459.003.0088.

Full text

Abstract:

Beta blocker and calcium channel blocker overdose is a rare perioperative complication that manifests with symptoms of altered mental status, hypotension, bradycardia, and cardiovascular collapse. Although the clinical presentation is often similar, the underlying pathophysiology can differ between either cardiogenic or vasodilatory shock. Standard therapies such as calcium administration or beta-adrenergic agonists may be effective but often require much higher doses than normal. The evidence for targeted therapies, such as high-dose insulin infusion and glucagon, is mixed, but these should b

APA, Harvard, Vancouver, ISO, and other styles

5

Isbister, Geoffrey, та Colin Page. Management of β‎-blocker and calcium channel blocker poisoning. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0325.

Full text

Abstract:

β‎-blocker and calcium channel-blockers can cause life-threatening toxicity due to cardiogenic shock. Both β‎-blockers and calcium channel-blockers are heterogenous groups of drugs and particular drugs, such as propranolol, diltiazem, and verapamil are far more toxic than the others in their class. The most important investigations in β‎-blocker and calcium channel-blocker overdose are an electrocardiogram, blood glucose measurement, and electrolytes. Like most overdoses, supportive treatment is the most important, with emphasis on the primary pathophysiology. Early decontamination should be c

APA, Harvard, Vancouver, ISO, and other styles

6

Frise, Matthew C., and Jonathan B. Salmon. Disorders of potassium in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0251.

Full text

Abstract:

Plasma potassium levels are maintained in health between 3.5 and 5.0 mmol/L, and reflect total body potassium only in stable states at normal pH. Most true hyperkalaemia results from renal insufficiency. The goals of therapy are myocardial protection and return of plasma potassium to a safe level. Measures are commonly initiated above 5.5 mmol/L; above 6.5 mmol/L, aggressive measures should be adopted and calcium salts given if there are cardiac dysrhythmias or QRS-broadening. Glucose-insulin infusions and beta-2-agonists promote potassium shifts into cells. Diuretics and sodium bicarbonate ma

APA, Harvard, Vancouver, ISO, and other styles

7

Esen, Figen. Disorders of magnesium in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0252.

Full text

Abstract:

Plasma potassium levels are maintained in health between 3.5 and 5.0 mmol/L, and reflect total body potassium only in stable states at normal pH. Most true hyperkalaemia results from renal insufficiency. The goals of therapy are myocardial protection and return of plasma potassium to a safe level. Measures are commonly initiated above 5.5 mmol/L; above 6.5 mmol/L, aggressive measures should be adopted and calcium salts given if there are cardiac dysrhythmias or QRS-broadening. Glucose-insulin infusions and beta-2-agonists promote potassium shifts into cells. Diuretics and sodium bicarbonate ma

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Insuline – Agonistes"

1

Loubatières-Mariani, Marie-Madeleine, Pierre Petit, Jeannie Chapal, Dominique Hillaire-Buys, Gyslaine Bertrand, and Gérard Ribes. "Effects of Purinoceptor Agonists on Insulin Secretion." In Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-2011-5_38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Malaisse-Lagae, F., A. Sener, and W. J. Malaisse. "Stimulation of Insulin Release by Organic Calcium-Agonists." In Advances in Experimental Medicine and Biology. Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-5314-0_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Richards, Steven. "Thiazolidinedione-Based Insulin Sensitizers:PPAR-γ Agonists for the Treatment of Type 2 Diabetes." In Bioactive Heterocyclic Compound Classes. Wiley-VCH Verlag GmbH & Co. KGaA, 2013. http://dx.doi.org/10.1002/9783527664450.ch20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Long, Harlan B., Rama M. Belagaje, Gerald S. Brooke, et al. "A-C-B human proinsulin: A novel insulin agonist and intermediate in the synthesis of human insulin." In Peptides. Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-011-2264-1_29.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chaouloff, F., V. Baudrie, and D. Laude. "Influence of 5-HT1A and 5-HT2 Receptor Agonists on Blood Glucose and Insulin Levels." In Serotonin: Molecular Biology, Receptors and Functional Effects. Birkhäuser Basel, 1991. http://dx.doi.org/10.1007/978-3-0348-7259-1_32.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Chlup, Rudolf, Richard Kaňa, Lada Hanáčková, Hana Zálešáková, and Blanka Doubravová. "Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020." In Type 2 Diabetes [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96237.

Full text

Abstract:

This overview summarizes the evolution of pathophysiologic treatment of diabetes type 2 (T2D) in the period of the last 40 years. Randomized Controlled Trials (RCT) and Real World Evidence (RWE) studies resulted in recent Statements of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) in the year 2020. Case reports and studies of a single-centre in Czech Republic are reported. The authors demonstrate the impact of (1) multiple doses of rapid insulin, (2) multiple doses of rapid or ultrarapid insulin analogs (3) continuous subcutaneous insulin infusion (CSII) (4) incretin receptor agonists, (5) fixed combination of insulin degludec with liraglutide (IDegLira) and (6) SGLT2 inhibitor dapagliflozin, on plasma glucose concentration, HbA1c, body mass and patient satisfaction. The importance of therapeutic patients´ education and technology (personal glucometers, continuous/flash glucose monitors, insulin pens/pumps) is emphasized. Most of the observations were already published. Hence, individually adopted education, lifstyle, technical equipment, incretin receptor agonists and/or metformin and/or gliflozins and/or insulin analogs appear to be the core of an effective pathophysiologic approach. Scientific conclusions from RCTs, RWE trials and own clinical case reports may prevail over clinical inertia and induce early implementation of effective methods into routine T2D treatment.

APA, Harvard, Vancouver, ISO, and other styles

7

Shah, Unmesh, and Timothy J. Kowalski. "GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders." In Incretins and Insulin Secretion. Elsevier, 2010. http://dx.doi.org/10.1016/b978-0-12-381517-0.00016-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Li, Jie Jack. "Sitagliptin (Januvia)." In Top Drugs. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780199362585.003.0012.

Full text

Abstract:

Diabetes has been known since antiquity. In fact, the term “diabetes mellitus” comes from the Greek meaning “siphon and honey” due to the excess excretion (siphon or faucet) of hyperglycemic (sweetened, or honeyed) urine associated with diabetes. In ancient times, diabetes was mostly type I, which usually manifests acutely in the young, secondary to certain underlying insults (possibly infections) to the islet cells of the pancreas resulting in an absolute lack of insulin. Insulin was discovered by Banting and Best in 1921, and insulin injection has literally saved millions of lives since then. With the wondrous efficacy that insulin bestows, type I diabetes is largely controlled because type I diabetes is insulindependent. However, type II diabetes, a more prevalent form of diabetes, is not insulin-dependent. In ancient times, when nutrition was scarce and obesity was not prevalent, type II diabetes mellitus (T2DM) was extremely rare. Indeed, type II diabetes is a disease more frequently associated with maturity, obesity, and gradually increasing blood glucose concentrations, and it may be asymptomatic for some time, only discovered on routine glucose screening. In fact, with the increasing body weight of the general population of the developed world, type II diabetes is becoming an epidemic. Serious complications of diabetes include nephropathy (kidney diseases), neuropathy (nerve damage), and retinopathy (blindness). Diabetes is the most common cause of blindness and amputation in the elderly in the United States. Oral diabetes drugs are required for most type II diabetic patients. Diabetes drugs may be classified into four categories: (a) agents that augment the supply of insulin such as sulfonylureas; (b) agents that enhance the effectiveness of insulin such as biguanides and thiazolidinediones; (c) GLP agonists; and (d) DPP4 Inhibitors. The efficacy of all the antidiabetic drugs can be monitored by measuring glycosylated hemoglobin (HaA1c) as a long term marker of elevated blood glucose. The amount of HaA1c reflects the average level over the last 120 days, the life span of a red blood cell, and should remain below 7%.

APA, Harvard, Vancouver, ISO, and other styles

9

Coughlan, Kimberly, Juli Jones, David Kubasiak, et al. "GLP1 Receptor Agonists Reduce Food Intake While Differentially Activating Neurons in the Hypothalamus and Hindbrain." In BASIC/TRANSLATIONAL - Insulin Action & Gut Hormones. The Endocrine Society, 2011. http://dx.doi.org/10.1210/endo-meetings.2011.part2.p8.p1-480.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Manov, Andrey Emanuilov, Ashan Thomas Hatharasinghe, and Katrina Equinox Lopez. "Comparison of the effect on Hyperglycemia and the Adverse Effects among Different GLP-1 Receptor Agonists Added to Basal Insulin and between GLP-1 Receptor Agonists and Basal Insulin Versus Basal-Plus or Basal-Bolus Insulin in Type 2 Diabetes: A Meta-Analysis." In New Frontiers in Medicine and Medical Research Vol. 10. Book Publisher International (a part of SCIENCEDOMAIN International), 2021. http://dx.doi.org/10.9734/bpi/nfmmr/v10/4105f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Insuline – Agonistes"

1

Nie, Zhenying, Becky Proskocil, David Jacoby, and Allison Fryer. "Potentiation effect of insulin on M3 muscarinic receptor agonist induced airway smooth muscle contraction." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zhang, Xihong, Sidhant Varma, and Douglas Yee. "Abstract 4406: Inducible knockdown of insulin receptor substrate I desensitizes ER alpha response to both agonist (estradiol) and antagonist (fulvestrant) in MCF-7L breast cancer cells." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4406.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!